Roots Analysis has announced the addition of “Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030” report to its list of offerings.

 

To order this 320+ page report, which features 45+ figures and 100+ tables, please visit this link

 

Key Market Insights

• Close to 130 industry and non-industry players, across the globe, claim to have the necessary expertise and supporting infrastructure to manufacture a wide variety of radioisotopes, for in-house use, or as a contract service
• The market is fragmented, featuring the presence of companies in both developed and developing nations, which are capable of manufacturing radiopharmaceuticals for various applications at different scales of production
• The growing interest in this field is reflected in the yearly growth in partnership activity; the majority of deals inked in the recent past include manufacturing and supply agreements for various types of radiopharmaceuticals
• Stakeholders are actively expanding their capabilities in order to enhance their respective nuclear medicine and radiopharmaceutical manufacturing capabilities and, thereby, maintain a competitive edge in this industry
• Case Study: The decay product of Mo-99, Tc-99m, is used in majority of the radioactivity-based diagnostic applications in the US; reactors in the European region alone contribute to 60% of the global production capacity
• In the long-term, the forecasted opportunity is anticipated to be higher for radioisotopes intended for diagnostic applications, mostly for use in the field of cardiology, with North America holding the dominant position
• SPECT and beta-emitters are anticipated to generate the majority share of revenues across diagnostic and therapeutic applications, respectively, for both in-house use and radiopharmaceutical supply contracts

 

For more information, please visit https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html

Table of Contents

 

1.         PREFACE
1.1.       Scope of the Report
1.2.       Research Methodology
1.3.       Chapter Outlines

2.         EXECUTIVE SUMMARY

3.         INTRODUCTION
3.1.       Chapter Overview
3.2.        Nuclear Medicines and Radiopharmaceuticals
3.3.        Historical Evolution of Radiopharmaceuticals
3.4.        Applications of Radiopharmaceuticals
3.4.1.     Nuclear Imaging / Diagnosis
3.4.1.1.  Single Photon Emission Computed Tomography
3.4.1.2.  Positron Emission Tomography
3.4.2.     Therapeutic Use

 

3.5.       Production of Radiopharmaceuticals
3.5.1.    Radionuclide Generator
3.5.2.    Particle Accelerator (Cyclotron)
3.5.3.    Nuclear Reactor

3.6.       Regulatory Framework for Radiopharmaceuticals
3.6.1.    Guidelines for the Production of Radiopharmaceuticals
3.6.2.    Guidelines for Labelling and Packaging of Radiopharmaceuticals
3.6.3.    Guidelines for Storage of Radiopharmaceuticals

3.7.       Need for Outsourcing Radiopharmaceuticals Manufacturing
3.8.       Selecting a CMO Partner for Radiopharmaceuticals Manufacturing
3.9.       Current Scenario and Future Prospects Related to Radiopharmaceuticals

 

 

4.         NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS (INDUSTRY PLAYERS): CURRENT MARKET LANDSCAPE
4.1.       Chapter Overview
4.2.       Nuclear Medicine and Radiopharmaceuticals Manufacturers: Overall Market Landscape
4.2.1.    Analysis by Year of Establishment
4.2.2.    Analysis by Company Size
4.2.3.    Analysis by Purpose of Production
4.2.4.    Analysis by Geographical Location of Headquarters
4.2.5.    Analysis by Geographical Location of Manufacturing Facilities
4.2.6.    Analysis by Scale of Production
4.2.7.    Analysis by Application Area
4.2.8.    Analysis by Type of Radioisotope
4.2.8.1. Radioisotopes for Diagnostic Use
4.2.8.2. Radioisotopes for Therapeutic Use

4.2.9     Analysis by Target Therapeutic Area
4.2.10   Analysis by Service(s) Offered

 

5.         NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS (NON-INDUSTRY PLAYERS): CURRENT MARKET LANDSCAPE
5.1.       Chapter Overview
5.2.       Nuclear Medicine and Radiopharmaceuticals Manufacturers: Overall Market Landscape
5.2.1.    Analysis by Year of Establishment
5.2.2.    Analysis by Purpose of Production
5.2.3.    Analysis by Geographical Location of Manufacturing Facilities
5.2.4.    Analysis by Scale of Production
5.2.5.    Analysis by Application Area
5.2.6.    Analysis by Type of Radioisotopes
5.2.6.1. Radioisotopes for Diagnostic Use
5.2.6.2. Radioisotopes for Therapeutic Use

 

6.         NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS IN NORTH AMERICA
6.1.       Chapter Overview
6.2.       Cardinal Health
6.2.1.    Company Overview
6.2.2.    List of Products and Manufacturing Facilities
6.2.3.    Recent Developments and Future Outlook 

6.3.       GE Healthcare
6.3.1.    Company Overview
6.3.2.    List of Products and Manufacturing Facilities
6.3.3.    Recent Developments and Future Outlook 

6.4.       Jubilant Radiopharma
6.4.1.    Company Overview
6.4.2.    List of Products and Manufacturing Facilities
6.4.3.    Recent Developments and Future Outlook 

6.5.       Lantheus Medical Imaging
6.5.1.    Company Overview
6.5.2.    List of Products and Manufacturing Facilities
6.5.3.    Recent Developments and Future Outlook 

6.6.       Nordion
6.6.1.    Company Overview
6.6.2.    List of Products and Manufacturing Facilities
6.6.3.    Recent Developments and Future Outlook 

6.7.       SOFIE
6.7.1.    Company Overview
6.7.2.    List of Products and Manufacturing Facilities
6.7.3.    Recent Developments and Future Outlook

 

7.         NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS IN EUROPE
7.1.       Chapter Overview
7.2.       Advanced Accelerator Applications
7.2.1.    Company Overview
7.2.2.    List of Products and Manufacturing Facilities
7.2.3.    Recent Developments and Future Outlook 

7.3.       SCK•CEN
7.3.1.    Company Overview
7.3.2.    List of Products and Manufacturing Facilities
7.3.3.    Recent Developments and Future Outlook 

7.4.       Curium Pharma
7.4.1.    Company Overview
7.4.2.    List of Products and Manufacturing Facilities
7.4.3.    Recent Developments and Future Outlook 

7.5.       Eckert & Ziegler
7.5.1.    Company Overview
7.5.2.    List of Products and Manufacturing Facilities
7.5.3.    Recent Developments and Future Outlook 

7.6.       PETNET Solutions
7.6.1.    Company Overview
7.6.2.    List of Products and Manufacturing Facilities
7.6.3.    Recent Developments and Future Outlook

 

8.         NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS IN ASIA-PACFIC AND REST OF THE WORLD
8.1.       Chapter Overview
8.2.       China Isotope & Radiation Corporation
8.2.1.    Company Overview
8.2.2.    List of Products and Manufacturing Facilities
8.2.3.    Recent Developments and Future Outlook 

8.3.       DuChemBio
8.3.1.    Company Overview
8.3.2.    List of Products and Manufacturing Facilities
8.3.3.    Recent Developments and Future Outlook 

8.4.       Eczacibasi-Monrol
8.4.1.    Company Overview
8.4.2.    List of Products and Manufacturing Facilities
8.4.3.    Recent Developments and Future Outlook 

8.5.       Nihon Medi-Physics
8.5.1.    Company Overview
8.5.2.    List of Products and Manufacturing Facilities
8.5.3.    Recent Developments and Future Outlook 

8.6.       Sinotau Pharmaceuticals
8.6.1.    Company Overview
8.6.2.    List of Products and Manufacturing Facilities
8.6.3.    Recent Developments and Future Outlook

 

9.         NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS: COMPANY COMPETITIVENESS ANALYSIS

9.1.       Chapter Overview

9.2.       Scope and Methodology

9.3.       Assumptions and Key Parameters

9.4.       Four-Dimensional Bubble Analysis based on Supplier Power, Product Portfolio Strength and Manufacturing Capabilities

9.4.1.    Nuclear Medicine and Radiopharmaceuticals Manufacturers based in North America

9.4.2     Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Europe

9.4.3.    Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Asia-Pacific and Rest of the World

 

10.        PARTNERSHIPS AND COLLABORATIONS
10.1.     Chapter Overview
10.2.     Partnership Models
10.3.     Nuclear Medicine and Radiopharmaceuticals Manufacturers: Partnerships and Collaborations
10.3.1.  Analysis by Type of Partnership
10.3.2. Analysis by Year of Partnership
10.3.3. Analysis by Type of Radioisotope
10.3.4. Analysis by Target Therapeutic Area Mentioned in the Agreement
10.3.5. Analysis by Application Mentioned in the Agreement
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.3.7. Geographical Analysis
10.3.8. Intercontinental and Intracontinental Agreements

 

11.        PRODUCTION AND SUPPLY CHAIN OF MEDICAL ISOTOPE MOLYBDENUM-99 (TECHNETIUM-99M)
11.1.     Chapter Overview
11.2.     Production and Use of Mo-99
11.2.1. Reactor-based Production
11.2.2. Accelerator-based Production

11.3.     Supply Chain of Mo-99
11.3.1. Target Suppliers
11.3.2. Irradiation Service Providers
11.3.3. Mo-99 Suppliers
11.3.4. Technetium Generator Suppliers
11.3.5. Tc-99m End-Users

11.4.     Future Prospects

 

 

12.        MARKET FORECAST AND OPPORTUNITY ANALYSIS

12.1.     Chapter Overview

12.2.     Forecast Methodology and Key Assumptions

12.3.     Overall Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030

12.3.1. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Target Therapeutic Area

12.3.2. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Application Area

12.3.3. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Diagnostic Radiopharmaceuticals

12.3.4. Nuclear Medicine and Radiopharmaceutical Manufacturing Market, 2020-2030: Distribution by Therapeutic Radiopharmaceuticals

12.3.5. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Purpose of Production

12.3.6.  Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by         Key Geographical Regions
 

13.        CONCLUDING REMARKS
13.1.     Chapter Overview
13.2.     Key Takeaways

 

14.        EXECUTIVE INSIGHTS
14.1.     Chapter Overview

14.2.     Shertech Laboratories
14.2.1. Company Snapshot
14.2.2. Interview Transcript: James Davis, Vice President Quality / R&D

14.3.     University of Ioannina
14.3.1. Organization Snapshot
14.3.2. Interview Transcript: Andreas Fotopoulos, Professor of Nuclear Medicine

14.4.     University Medical Center Groningen
14.4.1. Organization Snapshot
14.4.2. Interview Transcript: Jan Pruim, Professor of Medical Imaging / Nuclear Medicine Physician

14.5.     Crump Institute for Molecular Imaging, Molecular & Medical Pharmacology
14.5.1. Organization Snapshot
14.5.2. Interview Transcript: Michael van Dam, Professor

14.6.     ITM Isotopen Technologien München
14.6.1. Company Snapshot
14.6.2. Interview Transcript: Anonymous

 

15.        APPENDIX 1: TABULATED DATA

 

16.        APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com